Thus, by potently inhibiting HIF-2α and partially inhibiting HIF-1α, these compounds can be expected to exert maximal anti-tumor activity while maintaining a therapeutic window for minimal toxicity to normal tissue. The gene discussed is HIF1A; the disease is neoplasm.